<DOC>
	<DOCNO>NCT01199367</DOCNO>
	<brief_summary>This study determine high dose KW-2450 combination lapatinib letrozole administer safely subject advance metastatic breast cancer evaluate effectiveness . This study terminate Phase 1 never proceed Phase 2 portion study .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Study Subjects With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>This open-label , sequential , ascend , multi-dose , Phase 1/2 study enroll 198 post-menopausal subject advance metastatic breast cancer whose tumor overexpress HER2 . Subjects dose level receive KW-2450 orally , continuous daily schedule combination lapatinib letrozole . In Phase 1 portion study , dose escalation may proceed ≥ 3 subject complete Day 30 . The safety dose level establish prior enrollment subject next dose level . Dose escalation proceed sequentially . Up 6 subject may enrol dose level . Enrollment proceed MTD establish high dose level reach . The Phase 2 portion trial enroll 168 additional subject . The dose level base overall safety tolerability assessment Phase 1 portion study . The subject randomize two treatment arm ( 1 ) Arm A , KW-2450 plus lapatinib plus letrozole : ( 2 ) Arm B , lapatinib plus letrozole . This study terminate Phase 1 never proceed Phase 2 portion study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion Criteria 1 . Histopathologically cytologically confirm , advance metastatic breast cancer ( stage IIIb , IIIc IV disease ) include inflammatory breast cancer inoperable locally advanced disease . 2 . Documented ErbB2 overexpression 3 . Estrogen receptor positive ( ER+ ) and/or progesterone positive ( PgR+ ) tumor 4 . Measurable nonmeasurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Criteria 5 . A life expectancy &gt; 3 month Phase 1 &gt; 6 month Phase 2 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 2 study entry Phase 1 ≤ 1 Phase 2 ; 7 . Normal cardiac ejection fraction 8 . Adequate hematologic , hepatic renal function 9 . Postmenopausal female ( defined absence menstrual cycle least 12 consecutive month ) male subject ≥ 18 year age . 10 . Sign IRB EC approve informed consent Exclusion Criteria 1 . Type 1 diabetes uncontrolled Type 2 diabetes 2 . Subjects show clinical evidence history cataract ( ) , proliferate retinopathy significant macular edema 3 . Subjects abnormal free T4 value history evidence thyroid disease 4 . Subjects unable unwilling take metformin 5 . Uncontrolled intercurrent illness 6 . Known suspected human immunodeficiency virus ( HIV ) infection hepatitis B C 7 . Subjects inflammatory disease gastrointestinal tract 8 . History malignancy . Subjects disease free 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible ; 9 . Subjects extensive symptomatic visceral disease include hepatic involvement pulmonary lymphangitic spread tumor 10 . A history prior treatment agent specifically target IGFRs 11 . Subjects require pharmacological dos glucocorticoid beyond replacement dos . The use topical , intraocular inhalation glucocorticoid permit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>advanced metastatic breast cancer</keyword>
</DOC>